Full Picture

Article analysis:

The article is generally reliable and trustworthy, as it provides evidence for its claims through a panel data set from 2009 to 2017. The authors also provide detailed analysis of their findings, which adds credibility to their conclusions.

However, there are some potential biases that should be noted. First, the article does not explore any counterarguments or alternative perspectives on the issue at hand. Additionally, it does not consider any possible risks associated with government subsidies or other forms of public funding for research and development in the pharmaceutical industry. Furthermore, while the authors present their findings objectively, they do not present both sides of the argument equally; instead, they focus primarily on how government subsidies can benefit R&D investments and innovation performance in the Chinese pharmaceutical industry without considering any potential drawbacks or negative consequences that may arise from such policies. Finally, there is no mention of promotional content or partiality in this article; however, readers should still be aware that these factors could potentially influence its conclusions.